[Correspondence] Optimising standard of care in non-small-cell lung cancer trials – Authors’ reply
Source 柳叶刀 Lancetjust now
Summary
We thank Emma D A Wagener and Wouter H van Geffen for emphasising the importance of comparator selection. We agree that pembrolizumab plus platinum-based chemo…
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Health
- Region
- United Kingdom
- Language
- English
- Item ID
- health-514fc802
Comments 0 comments
No comments yet. Be the first.